Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580591 · ClinicalTrials.gov registry record · Phase 3
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 977
- Enrollment target
NCT02580591 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 977 participants.
The verdict
NCT02580591, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 977 participants
- Enrollment target
Study Summary
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
Interventions
- DRUG Placebo
- DRUG Empagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 977 participants |
| Start Date | 2015-12-22 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02580591
The ClinicalTrials.gov registry entry for NCT02580591 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 977 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02580591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02580591 about?
NCT02580591 is a clinical study titled "Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)". The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
What is the current status of trial NCT02580591?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 977 participants. The study started on 2015-12-22. Estimated completion is 2017-09-20.
What interventions are being tested in trial NCT02580591?
The interventions under investigation include: Placebo (DRUG), Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT02580591?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.